About Us

Elastagen is a clinical stage medical company with an advanced pipeline of products based on the human protein tropoelastin, a pioneering medical biomaterial.

Elastin is a critical component of tissues in the human body which require the ability to stretch and recoil, such as the skin, lungs, arteries, elastic ligaments.  Elastagen has developed a synthetic version of the elastin protein which is identical to that naturally present in the human body.

Elastagen’s platform technology has potential applications in a number of areas including skin rejuvenation, scar remodelling, skin tissue repair and wound healing, and, surgical glues / sealants.

Elastagen has a strong commitment to scientific and clinical excellence in the development of its tropoelastin based products, and has received endorsements of its scientific and clinical excellence from the NSW Department of Health.

Elastagen began operations in 2005 following seed funding from ATP Innovations and the acquisition of intellectual property rights to the elastin technology which was developed by Prof Weiss at the University of Sydney,  The company started the commercially and clinically focused phase of its business in August 2008, following Series A financing by leading Australian venture investors including GBS Ventures and Brandon Capital Partners together with ATP Innovations.

Elastagen’s operations have expanded from its Australian base to include production in Europe, clinical operations in the UK, and a product development program in collaboration with groups in Europe and the US.

Our People | Team

X

Rob Daniels

DIRECTOR & CEO

Rob has successfully guided Elastagen from its early research phases through to the current clinical development of its tropoelastin based treatments for the rapidly growing medical and aesthetic markets.

Prior to joining Elastagen Rob had spent the previous ten years working across a broad range of the life science industry including contract research, medical devices and therapeutics. He has been successful in raising capital; managing in- and out- licensing programs; joint venture creation; and, managing product development programs through to the clinic. Robert’s experience includes University spin-outs through to listed companies; and, he has worked in the UK, Australia and Hong Kong.

Most recently he was VP Asia Pacific for PharmaVentures Ltd, a boutique transaction advisory firm specialising in the life sciences. Prior to that Robert was Chief Commercial Officer at Novathera Ltd where he gained significant domain experience in the regenerative medicine field.

Robert has a PhD from University College London and a Masters in Entrepreneurship and Innovation from the Australian Graduate School of Entrepreneurship.

X

John St Clair Roberts (MRCS LRCP FFPM)

MEDICAL DIRECTOR

Having graduated in medicine from the Royal College of Surgeons in Ireland, John chose to specialise in Pharmaceutical Medicine after spending several years practicing hospital-based medicine in the UK, and working for the flying-doctor service in Kenya.

Within the pharmaceutical industry, he has since gained significant development and business experience in a broad range of therapeutic areas including vaccination, immunotherapy, infectious disease, oncology, wound healing, aesthetics, regenerative medicine and addiction. John has first-hand experience of all phases of clinical development with a particular emphasis on practical design and fast track delivery of phase I and phase II proof-of-concept studies.

He has a strong commercial awareness having held senior management and executive board positions in both private and public pharmaceutical companies including Merieux UK (now Sanofi-Pasteur MSD), Cantab Pharmaceuticals plc, Xenova Group plc, Microscience plc and Intercytex plc. John has been responsible for numerous clinical studies in Europe, North America, Australasia, India and Vietnam.

X

Michal Graff Mitzmacher

CHIEF TECHNOLOGY OFFICER

Michal has driven the transition of Elastagen’s technology from proof of concept production runs through scale up to commercial production and industrial processes; enabling Elastagen’s unique tropoelastin based materials to be produced to the required economies of scale. In addition, Michal has been central to Elastagen’s partnering activities with responsibility for the capture, communication and transfer of Elastagen’s technology to and from partner facilities.

Michal is an accomplished Engineer with significant experience in the Pharmaceuticals, Medical Device and Biotechnology industries. Michal’s experience includes deep hands-on roles in all aspects of pharmaceutical research, production, scale up and design, as well as in the construction, commissioning, simulation and operation of industrial processes and clean systems.

Most recently she was Project Leader & Senior Engineer for Biopharmax LTD, a boutique design and construction consultancy firm specialising in the life sciences. One of her roles at Biopharmax was as project engineer for Omrix and subsequently J&J; a role which included the scale-up of production processes for the manufacture of their fibrin biomaterial; the design, construction, commission and simulation of the production plant; together with close liaison and coordination with the client.

Michal has a M.Sc in Bio-material Engineering from Tel-Aviv University and a B.Sc in Chemical Engineering from the Technion, Israel.

X

John Westwater

CHIEF FINANCIAL OFFICER

John is our Chief Financial Officer and joined the Company in 2015. He has over thirteen years experience in the life science financial industry, eight years as a venture capital investor and remainder as an investment banking professional.

Prior to joining Elastagen he was at Phase4 Ventures (formerly Nomura Phase4 Ventures), a global life science VC firm based in London. During this period he was actively involved with several investments both in the US and Europe: including Nabriva Therapeutics, Paratek Pharmaceuticals, Zosano Pharma and Acadia Pharmaceuticals.

John has also spent over four years with Morgan Stanley in their healthcare corporate finance and Mergers & Acquisitions teams. During this period he had a key role in the development and execution of Elan Corp’s recovery plan between 2002 and 2003, which involved over $1Bn in disposal proceeds and the restructuring of its balance sheet, as well as several biotech initial public offerings.
He holds a PhD and BSc (Hons) in Biochemistry from Heriot-Watt University in Scotland and was awarded the Watt Club Medal.

X

Emma McGilly

ADMINISTRATION & EXECUTIVE ASSISTANT

Emma is Elastagen’s Administrative and Executive Assistant with over 20 years experience in administration, office management and customer service.

Prior to Elastagen, Emma worked as a Firm Administrator for Webb Henderson, a premium international legal and regulatory practice; Office Manager and Administrative Assistant at Sweeney Vesty, a business strategy and communications company providing services to corporations and public organisations; and, as an Export Co-ordinator for PSM Healthcare Ltd (now API Consumer Brands), a world-class company in manufacturing healthcare, pharmaceutical and skincare products in New Zealand.

Our People | Board

X

Rob Daniels

DIRECTOR & CEO

Rob has successfully guided Elastagen from its early research phases through to the current clinical development of its tropoelastin based treatments for the rapidly growing medical and aesthetic markets.

Prior to joining Elastagen Rob had spent the previous ten years working across a broad range of the life science industry including contract research, medical devices and therapeutics. He has been successful in raising capital; managing in- and out- licensing programs; joint venture creation; and, managing product development programs through to the clinic. Robert’s experience includes University spin-outs through to listed companies; and, he has worked in the UK, Australia and Hong Kong.

Most recently he was VP Asia Pacific for PharmaVentures Ltd, a boutique transaction advisory firm specialising in the life sciences. Prior to that Robert was Chief Commercial Officer at Novathera Ltd where he gained significant domain experience in the regenerative medicine field.

Robert has a PhD from University College London and a Masters in Entrepreneurship and Innovation from the Australian Graduate School of Entrepreneurship.

 

X

Andrew Sneddon

CHAIRMAN

Andrew was appointed to the Board of Elastagen Pty Ltd as Chairman in September 2008. Andrew is a former partner of PricewaterhouseCoopers (PWC). In his PWC role, Andrew led the technology practise for a period of time and specialised in fast growth and emerging technology companies working with many companies from start-ups to successful global corporations.

In more recent years he was the partner leading the firm’s Australian Life Sciences Practice. Andrew has extensive experience in a wide range of technical areas including mergers and acquisitions, business and strategic planning, audit, valuation, capital raising and stock exchange listings on the Australian, NASDAQ and London Stock Exchanges.

He has worked across a broad range of industries and is currently a Non-Executive Director of Innate Immunotherapeutics Limited, ClearView Wealth Limited and the Chairman of ServiceRocket Inc, Fusion Payments Limited and TGR BioSciences Pty Ltd. He is also a member of the Audit and Compliance Committees of the Crescent Capital Private Equity Funds.

X

Xavier Yon

NON-EXECUTIVE DIRECTOR

Xavier Yon is a seasoned healthcare executive with an extensive background in dermatology. Previous roles include executive positions with Pfizer, Solvay, Alcon and most notably as CEO of Galderma for 17 years. During his time at Galderma he built the company from its initial spin out from Alcon to be a world leader in ethical dermatology.

Galderma currently has over 3,000 employees and $2 Billion in revenue. More recently Xavier has served as a Director of Graceway Pharmaceuticals (USA), which was acquired by Medicis in 2011. In addition to his position with Elastagen, Xavier currently serves as a board member of Photocure (Norway), a pioneer of Photo Dynamic Therapy, and Virbac (France), a global leader in animal health.

Xavier holds a degree in Physics, Chemistry and Biology from Sorbonne University, Paris and attended the Advanced Management Program at Harvard University.

X

Joshua Funder

DIRECTOR

Dr Joshua Funder joined GBS in 2004 and has more than 17 years experience in biotechnology research, management and venture investing. Before joining GBS, Joshua worked in corporate strategy and development at Infinity Pharmaceuticals in Boston and the Boston Consulting Group in San Francisco. In addition, he worked with the Clinton Foundation HIV/AIDS Initiative to successfully negotiate reduced prices for anti-retrovirals and initiate pharmaceutical supplies across eastern and southern Africa. Joshua has experience as founder, director and chairman of biotechnology companies in Australia and the US and brings extensive experience of international venture syndication. He served as interim CEO of Proacta Inc following GBS investment and is on the board of directors of GBS portfolio companies Celladon Corporation (NASDAQ:CLDN), Spinifex Pharmaceuticals Inc, Neurovance Inc, Euthymics Inc and Elastagen Pty Ltd.  Joshua was director of GBS investee company Peplin Inc (ASX:PLI) which won the AVCAL award for the best early stage investment in 2010.

Joshua earned his Bachelor of Science (Honours) and Bachelor of Laws (Honours) degrees at Melbourne University and his Master of Laws degree at the London School of Economics. He holds a D.Phil in intellectual property for biotechnology from Oxford University where he studied as a Rhodes Scholar.

X

Stephen Thompson

DIRECTOR

Stephen is a founding partner of Brandon Capital Partners. Previously Stephen worked with Bio Innovation SA and helped establish Terra Rossa Capital, a dedicated life science Fund Manager in Adelaide.

Prior to this Stephen was a Director of Apax Partners a leading international private equity group based in London. During this time he was also a Director of Imperial Innovations, the commercialisation company of Imperial College London. Before joining Apax Partners, he fulfilled roles in product development with UK biotechnology company Cantab Pharmaceuticals. Earlier, Stephen spent ten years as a research immunologist in London and California.

Stephen is a Director of Elastagen P/L, MiReven P/L, Vaxxas P/L, Helmedix P/L, Auspherix P/L and Council Member of the Australian Venture Capital Association Limited (AVCAL). Stephen has an Honours degree in Immunology and Biochemistry, a PhD in Immunology from Kings College London and an MBA, specialising in Entrepreneurship, from Imperial College London. Stephen is a Graduate of the Australian Institute of Company Directors and a member of AusBiotech.

X

Hamish Hawthorn

DIRECTOR

Hamish is the Chief Executive Officer of ATP Innovations – Australia’s premier technology business incubator. ATP Innovations delivers commercialisation and business expertise to emerging technology businesses, helping entrepreneurs build successful high-growth companies. Hamish has been involved in the commercialisation of technology for over 15 years and worked in the advanced manufacturing, IT and life sciences sectors. In late 2008, Hamish co-founded Sydney Angels – a Sydney-based Angel group that invests in early stage high-growth companies.

Hamish is a Visiting Fellow in the Entrepreneurs in Science Program at the University of New South Wales, and lectures on entrepreneurship at the University of Sydney, the University of Technology, Sydney and the Australian National University.

He is a qualified mechanical engineer with postgraduate training in business and technology.

Our People | Scientific Advisors

Scientific Advisor Tony Weiss
Prof Tony Weiss
Founder / Lead Scientific Advisor

 

Professor Tony Weiss is the world leader in human tropoelastin and elastin research and its applications. A multiple University prize winner, Fulbright Scholar and learned society medalist, he is the main inventor and scientific expert behind the Intellectual Property licensed by Elastagen from the University of Sydney.

He is the Professor of Biochemistry & Molecular Biotechnology at the University of Sydney and holds multiple visiting and honorary appointments nationally and internationally. He is a Fellow of the Royal Society of Chemistry, Fellow of the Australian Academy of Technological Sciences and Engineering, Fellow of the American Institute for Medical and Biological Engineering, Fellow of the Royal Society of Arts and Fellow of the Australian Institute of Company Directors. He is on the Editorial Boards of ACS Biomaterials Science and Engineering, Biomacromolecules, Biomaterials, Biomedical Materials, BioNanoScience and Tissue Engineering.

He established the leading international human tropoelastin research laboratory and for over the past two decades has significantly increased our understanding of the expression, handling and applications of human tropoelastin.

Our People | Investors

Elastagen is a venture capital backed private company and has been successful in attracting funding from some of Australia’s leading life science investment groups.

The following investors currently have a stake in Elastagen:

investor-gbs-venture-partners

GBS Venture Partners

Founded in 1996, GBS invests in young businesses developing and commercialising products which, when combined with the right management and finance, will make a significant difference to patients’ lives and deliver financial returns for our investors. Our areas of particular interest and expertise include human healthcare, biotechnology product development and life science start-ups. In particular, recent investments have included biological or small molecule therapeutics, medical devices and diagnostics.

For more information on GBS Venture Partners please visit:
www.gbsventures.com.au.

investor-brandon-capital-partners

Brandon Capital Partners

Brandon Capital Partners was founded in 2007 and makes seed and venture capital investments into emerging businesses in the high-growth life science industry. In addition to capital, Brandon enables entrepreneurs to access the resources needed to build successful businesses. We approach each investment as a collaborative alliance. Brandon’s team has a track record of successful life science investment as well as a history of working in research, operations and business development in the life sciences industry.

For more information on Brandon Capital Partners please visit:
www.brandoncapital.com.au.

investor-atp-innovations

BizCapital Pty Ltd

BizCapital is the investment fund of ATP Innovations – Australia’s leading business incubator. ATP Innovations has a portfolio of over 50 companies in the life sciences, engineering and information technology sectors. The company is based at the Australian Technology Park, delivering value to early-stage companies and accelerating their path to success. ATP Innovations is owned by four of Australia’s premier universities – the University of Sydney, the University of New South Wales, the Australian National University and the University of Technology, Sydney.

For more information on bizCapital and ATP Innovations please visit:
www.atp-innovations.com.

In addition to the above private investment Elastagen has also received significant support from programs managed by both the NSW State government (NSW Medical Devices Fund, NSW Biobusiness, DSRD) and Australian Federal government (NCRIS, R&D tax offset and Export Market Development).

Our Technology

Elastagen is a medical company with an advanced pipeline of products based on recombinant human tropoelastin, the building block of elastin.

Elastin is a critical physical and biological component of human tissues, such as the skin, lungs, arteries, and elastic ligaments, and is comprised of multiple copies of the protein tropoelastin.

Elastin is produced in the body predominantly during foetal development and by the time we reach adulthood the ability of the body to express tropoelastin and regenerate new elastin is minimal.

The application of tropoelastin and/or elastin as a medical biomaterial has to date been limited due to the inability to extract the protein in a functional form from animal tissues or produce it synthetically.

Elastagen, through its founding scientist Prof Weiss and his team at the University of Sydney, has acquired a unique and dominant position in the tropoelastin and elastin field.  Elastagen is the first and only provider of full length, scalable, commercial cGMP clinical grade human tropoelastin. Furthermore, Elastagen has pioneered the scientific understanding of tropoelastin and the “elastagenesis” process and developed and patented a range of approaches to formulate tropoelastin for application in tissue repair.

Tropoelastin has huge advantages for a range of medical applications, including its unique physical elastic properties and its ability to support cell growth and tissue repair. In addition, as a recombinant human biomaterial our tropoelastin based polymers have an ideal biocompatibility profile and no immune rejection problems.

Elastagen’s vision is to exploit the unique properties of the elastin material in its target medical applications through to clinical proof of concept prior to partnering for market entry and sales.

Our Products

Elastagen has an advanced portfolio of products built on scientific and clinical excellence which has been validated by preclinical and clinical studies.

Elastagen Pipeline
Elastagen Products

R&D Product Sales

Recombinant Human Tropoelastin

Cat No: ELA-1

Description:       Tropoelastin is a 60kDa extracellular matrix protein and is the soluble precursor to elastin.

Elastin is a key mammalian extracellular matrix protein that is critical to the elasticity, compliance, and resilience of a range of tissues including the vasculature, skin, and lung. In addition to providing mechanical integrity to tissues, elastin also has critical functions in the regulation of cell behaviour.

For Research Use Only

Size:                      5mg

Price:                    $1250.00 ex GST*

(*GST Australia Only)

Freight:                POA


Placing Your Order

CLICK HERE TO PLACE AN ORDER

Orders Forms can be faxed to +61 (2) 9310 7232 or email to sales@elastagen.com.

Click below to buy online using PayPal


Other Information

Product Information Sheet

MSDS

Terms and Conditions

Privacy Policy


EXPRESSIONS OF INTEREST
 

Elastagen welcomes expressions of interest in its activities from both clinicians and commercial partners. In addition, given the preclinical and clinical platform which Elastagen has developed to date, we welcome contact from potential partners interested in the unique physical and biological properties of tropoelastin.

News

The latest Elastagen media coverage and break throughs

New Grants to Support Research Commercialisaton
April 15, 2015

Wellcome Trust Support for Transformative Tropoelastin Biomaterials
January, 2015

ELA presents at 7th Annual Biotech Showcase 2015 – San Francisco
January 13, 2015

Elastagen featured in Ahead of the Curve – Future Proof: The Investment Case for Biotech
December, 2014

ELA presents at Australia Biotech Invest 2014 – Melbourne
December 4, 2014

Elastagen presents at The 19th MedTech Investing Europe Conference – Paris
September 23, 2014

Elastagen recipient of inaugural NSW Health Medical Devices Fund 2013
July 15, 2013

Clinical Program Demonstrates Role for Elastin Products in Skin Repair and Rejuvenation
December 20, 2012

Elastagen Strengthens Board with Appointment of Xavier Yon
December 3, 2011

Elastagen Featured in Prime Magazine
October 11, 2011

The Science of Elastin
February, 2011

Elastagen Expands Clinical Program for Elastin Products
September 11, 2011

Skin Elastin Products A Significant Step Closer
December 11, 2009

Elastagen Secures Financing and Appoints Management Team
December 11, 2008

Literature

Literature resources to help you understand our processes and technology

CLICK HERE FOR SCIENTIFIC REFERENCES

elastagen-literature

Contact Us

For more information or product sales please contact us

Address

Elastagen Pty Ltd,
Australian Technology Park,
National Innovation Centre,
4 Cornwallis Street,
Eveleigh,
Sydney,
NSW 2015,
Australia

Phone

+61 (0)2 9209 4054

Email

info@elastagen.com

Your Name (required)

Your Email (required)

Subject

Your Message

Expressions of Interest

Elastagen welcomes expressions of interest in its activities from both clinicians and commercial partners. In addition, given the preclinical and clinical platform which Elastagen has developed to date, we welcome contact from potential partners interested in the unique physical and biological properties of tropoelastin.

Elastagen ATPi